Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
暂无分享,去创建一个
L. Schwartz | J. Sosman | J. Koutcher | E. Donnelly | A. Lockhart | J. Dupont | D. Spriggs | M. Rothenberg | W. Tew | P. Chevalier | D. Gultekin | L. Sternås | W. Cooper | I. Dancy | G. Buzenet | E. Koehler | R. Andal
[1] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[2] G. Yancopoulos,et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade , 2007, Proceedings of the National Academy of Sciences.
[3] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[4] Janet Rossant,et al. Endothelial cells and VEGF in vascular development , 2005, Nature.
[5] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[6] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] M V Knopp,et al. Dynamic contrast-enhanced magnetic resonance imaging in oncology. , 2001, Topics in magnetic resonance imaging : TMRI.
[8] N. Ferrara. VEGF: an update on biological and therapeutic aspects. , 2000, Current opinion in biotechnology.
[9] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[10] M. Knopp,et al. Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.
[11] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[12] Anthony J. Guidi,et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma , 1996, Cancer.
[13] Anthony J. Guidi,et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. , 1995, Journal of the National Cancer Institute.
[14] E. Manseau,et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.
[15] E. Manseau,et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.
[16] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[17] P. Tofts,et al. Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.
[18] D. Connolly,et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.
[19] H. Dvorak,et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.
[20] S. Kety. The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.
[21] W. Reinhold,et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.
[22] H. Weinmann,et al. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.